nodes	percent_of_prediction	percent_of_DWPC	metapath
Azelastine—CYP2E1—liver cancer	0.266	0.503	CbGaD
Azelastine—CYP1A1—liver cancer	0.263	0.497	CbGaD
Azelastine—CYP2B6—Sorafenib—liver cancer	0.0424	0.143	CbGbCtD
Azelastine—CYP3A5—Sorafenib—liver cancer	0.0334	0.113	CbGbCtD
Azelastine—CYP2C8—Sorafenib—liver cancer	0.0321	0.108	CbGbCtD
Azelastine—CYP2C19—Sorafenib—liver cancer	0.027	0.0908	CbGbCtD
Azelastine—CYP2B6—Doxorubicin—liver cancer	0.0257	0.0867	CbGbCtD
Azelastine—CYP1A2—Sorafenib—liver cancer	0.0249	0.0838	CbGbCtD
Azelastine—CYP2C9—Sorafenib—liver cancer	0.0224	0.0755	CbGbCtD
Azelastine—ABCB1—Sorafenib—liver cancer	0.0218	0.0733	CbGbCtD
Azelastine—CYP2D6—Sorafenib—liver cancer	0.0205	0.0691	CbGbCtD
Azelastine—ABCB1—Doxorubicin—liver cancer	0.0132	0.0445	CbGbCtD
Azelastine—CYP3A4—Sorafenib—liver cancer	0.013	0.0439	CbGbCtD
Azelastine—CYP2D6—Doxorubicin—liver cancer	0.0124	0.0419	CbGbCtD
Azelastine—CYP3A4—Doxorubicin—liver cancer	0.00791	0.0266	CbGbCtD
Azelastine—Aphthous stomatitis—Sorafenib—liver cancer	0.00269	0.0355	CcSEcCtD
Azelastine—Mucosal inflammation—Sorafenib—liver cancer	0.00227	0.0301	CcSEcCtD
Azelastine—Glossitis—Sorafenib—liver cancer	0.00137	0.0181	CcSEcCtD
Azelastine—Influenza like illness—Sorafenib—liver cancer	0.00122	0.0162	CcSEcCtD
Azelastine—Mouth ulceration—Sorafenib—liver cancer	0.00114	0.0151	CcSEcCtD
Azelastine—Furunculosis—Epirubicin—liver cancer	0.00109	0.0145	CcSEcCtD
Azelastine—Dysaesthesia—Epirubicin—liver cancer	0.00108	0.0142	CcSEcCtD
Azelastine—Eczema—Sorafenib—liver cancer	0.00102	0.0135	CcSEcCtD
Azelastine—Furunculosis—Doxorubicin—liver cancer	0.00101	0.0134	CcSEcCtD
Azelastine—Ulcerative stomatitis—Epirubicin—liver cancer	0.00101	0.0133	CcSEcCtD
Azelastine—Dysaesthesia—Doxorubicin—liver cancer	0.000996	0.0132	CcSEcCtD
Azelastine—Aphthous stomatitis—Epirubicin—liver cancer	0.000993	0.0131	CcSEcCtD
Azelastine—Furuncle—Epirubicin—liver cancer	0.000949	0.0126	CcSEcCtD
Azelastine—Ulcerative stomatitis—Doxorubicin—liver cancer	0.000933	0.0123	CcSEcCtD
Azelastine—Aphthous stomatitis—Doxorubicin—liver cancer	0.000918	0.0121	CcSEcCtD
Azelastine—Furuncle—Doxorubicin—liver cancer	0.000878	0.0116	CcSEcCtD
Azelastine—Mucosal inflammation—Epirubicin—liver cancer	0.000841	0.0111	CcSEcCtD
Azelastine—Nasopharyngitis—Sorafenib—liver cancer	0.000818	0.0108	CcSEcCtD
Azelastine—Alanine aminotransferase increased—Sorafenib—liver cancer	0.000806	0.0107	CcSEcCtD
Azelastine—Mucosal inflammation—Doxorubicin—liver cancer	0.000778	0.0103	CcSEcCtD
Azelastine—Parosmia—Epirubicin—liver cancer	0.000718	0.00949	CcSEcCtD
Azelastine—Epistaxis—Sorafenib—liver cancer	0.000665	0.00879	CcSEcCtD
Azelastine—Parosmia—Doxorubicin—liver cancer	0.000664	0.00878	CcSEcCtD
Azelastine—Laryngitis—Epirubicin—liver cancer	0.000646	0.00854	CcSEcCtD
Azelastine—Albuminuria—Epirubicin—liver cancer	0.000623	0.00825	CcSEcCtD
Azelastine—Laryngitis—Doxorubicin—liver cancer	0.000597	0.0079	CcSEcCtD
Azelastine—Flushing—Sorafenib—liver cancer	0.000587	0.00776	CcSEcCtD
Azelastine—Albuminuria—Doxorubicin—liver cancer	0.000577	0.00763	CcSEcCtD
Azelastine—Ageusia—Epirubicin—liver cancer	0.000575	0.0076	CcSEcCtD
Azelastine—Stinging—Epirubicin—liver cancer	0.000575	0.0076	CcSEcCtD
Azelastine—Dysgeusia—Sorafenib—liver cancer	0.000539	0.00713	CcSEcCtD
Azelastine—Breast pain—Epirubicin—liver cancer	0.000533	0.00706	CcSEcCtD
Azelastine—Ageusia—Doxorubicin—liver cancer	0.000532	0.00703	CcSEcCtD
Azelastine—Stinging—Doxorubicin—liver cancer	0.000532	0.00703	CcSEcCtD
Azelastine—Amenorrhoea—Epirubicin—liver cancer	0.00053	0.00701	CcSEcCtD
Azelastine—Viral infection—Epirubicin—liver cancer	0.000515	0.00682	CcSEcCtD
Azelastine—Thinking abnormal—Epirubicin—liver cancer	0.000508	0.00672	CcSEcCtD
Azelastine—Glossitis—Epirubicin—liver cancer	0.000505	0.00668	CcSEcCtD
Azelastine—Lacrimation increased—Epirubicin—liver cancer	0.000505	0.00668	CcSEcCtD
Azelastine—Herpes simplex—Epirubicin—liver cancer	0.000505	0.00668	CcSEcCtD
Azelastine—Breast pain—Doxorubicin—liver cancer	0.000494	0.00653	CcSEcCtD
Azelastine—Ulcer—Epirubicin—liver cancer	0.000492	0.00651	CcSEcCtD
Azelastine—Amenorrhoea—Doxorubicin—liver cancer	0.00049	0.00648	CcSEcCtD
Azelastine—Cough—Sorafenib—liver cancer	0.00048	0.00635	CcSEcCtD
Azelastine—Viral infection—Doxorubicin—liver cancer	0.000477	0.00631	CcSEcCtD
Azelastine—Hypertension—Sorafenib—liver cancer	0.000475	0.00629	CcSEcCtD
Azelastine—Thinking abnormal—Doxorubicin—liver cancer	0.00047	0.00622	CcSEcCtD
Azelastine—Myalgia—Sorafenib—liver cancer	0.000469	0.0062	CcSEcCtD
Azelastine—Lacrimation increased—Doxorubicin—liver cancer	0.000467	0.00618	CcSEcCtD
Azelastine—Herpes simplex—Doxorubicin—liver cancer	0.000467	0.00618	CcSEcCtD
Azelastine—Glossitis—Doxorubicin—liver cancer	0.000467	0.00618	CcSEcCtD
Azelastine—Dermatitis contact—Epirubicin—liver cancer	0.00046	0.00608	CcSEcCtD
Azelastine—Dry mouth—Sorafenib—liver cancer	0.000458	0.00606	CcSEcCtD
Azelastine—Ulcer—Doxorubicin—liver cancer	0.000455	0.00602	CcSEcCtD
Azelastine—Influenza like illness—Epirubicin—liver cancer	0.000452	0.00598	CcSEcCtD
Azelastine—Anaphylactic shock—Sorafenib—liver cancer	0.000449	0.00594	CcSEcCtD
Azelastine—Infection—Sorafenib—liver cancer	0.000446	0.0059	CcSEcCtD
Azelastine—Dermatitis contact—Doxorubicin—liver cancer	0.000426	0.00563	CcSEcCtD
Azelastine—Mouth ulceration—Epirubicin—liver cancer	0.000421	0.00557	CcSEcCtD
Azelastine—Influenza like illness—Doxorubicin—liver cancer	0.000418	0.00553	CcSEcCtD
Azelastine—Musculoskeletal discomfort—Sorafenib—liver cancer	0.000409	0.00541	CcSEcCtD
Azelastine—Abnormal vision—Epirubicin—liver cancer	0.000406	0.00537	CcSEcCtD
Azelastine—Mental disability—Epirubicin—liver cancer	0.000404	0.00534	CcSEcCtD
Azelastine—Dyspnoea—Sorafenib—liver cancer	0.000401	0.0053	CcSEcCtD
Azelastine—Mouth ulceration—Doxorubicin—liver cancer	0.000389	0.00515	CcSEcCtD
Azelastine—Fatigue—Sorafenib—liver cancer	0.000387	0.00512	CcSEcCtD
Azelastine—Pain—Sorafenib—liver cancer	0.000384	0.00508	CcSEcCtD
Azelastine—Constipation—Sorafenib—liver cancer	0.000384	0.00508	CcSEcCtD
Azelastine—Eczema—Epirubicin—liver cancer	0.000376	0.00497	CcSEcCtD
Azelastine—Abnormal vision—Doxorubicin—liver cancer	0.000376	0.00497	CcSEcCtD
Azelastine—Eye pain—Epirubicin—liver cancer	0.000374	0.00495	CcSEcCtD
Azelastine—Mental disability—Doxorubicin—liver cancer	0.000374	0.00494	CcSEcCtD
Azelastine—Gastrointestinal pain—Sorafenib—liver cancer	0.000367	0.00486	CcSEcCtD
Azelastine—Increased appetite—Epirubicin—liver cancer	0.00036	0.00476	CcSEcCtD
Azelastine—Abdominal pain—Sorafenib—liver cancer	0.000355	0.0047	CcSEcCtD
Azelastine—Body temperature increased—Sorafenib—liver cancer	0.000355	0.0047	CcSEcCtD
Azelastine—Anaphylactoid reaction—Epirubicin—liver cancer	0.000349	0.00462	CcSEcCtD
Azelastine—Eczema—Doxorubicin—liver cancer	0.000348	0.0046	CcSEcCtD
Azelastine—Eye pain—Doxorubicin—liver cancer	0.000346	0.00458	CcSEcCtD
Azelastine—Increased appetite—Doxorubicin—liver cancer	0.000333	0.0044	CcSEcCtD
Azelastine—Hypersensitivity—Sorafenib—liver cancer	0.000331	0.00438	CcSEcCtD
Azelastine—Face oedema—Epirubicin—liver cancer	0.000326	0.00431	CcSEcCtD
Azelastine—Anaphylactoid reaction—Doxorubicin—liver cancer	0.000323	0.00427	CcSEcCtD
Azelastine—Asthenia—Sorafenib—liver cancer	0.000322	0.00426	CcSEcCtD
Azelastine—Pruritus—Sorafenib—liver cancer	0.000318	0.0042	CcSEcCtD
Azelastine—Diarrhoea—Sorafenib—liver cancer	0.000307	0.00407	CcSEcCtD
Azelastine—Nasopharyngitis—Epirubicin—liver cancer	0.000302	0.004	CcSEcCtD
Azelastine—Face oedema—Doxorubicin—liver cancer	0.000302	0.00399	CcSEcCtD
Azelastine—Alanine aminotransferase increased—Epirubicin—liver cancer	0.000298	0.00394	CcSEcCtD
Azelastine—Dizziness—Sorafenib—liver cancer	0.000297	0.00393	CcSEcCtD
Azelastine—Asthma—Epirubicin—liver cancer	0.000292	0.00386	CcSEcCtD
Azelastine—Vomiting—Sorafenib—liver cancer	0.000286	0.00378	CcSEcCtD
Azelastine—Rash—Sorafenib—liver cancer	0.000283	0.00375	CcSEcCtD
Azelastine—Dermatitis—Sorafenib—liver cancer	0.000283	0.00374	CcSEcCtD
Azelastine—Headache—Sorafenib—liver cancer	0.000281	0.00372	CcSEcCtD
Azelastine—Bronchitis—Epirubicin—liver cancer	0.000281	0.00371	CcSEcCtD
Azelastine—Nasopharyngitis—Doxorubicin—liver cancer	0.00028	0.0037	CcSEcCtD
Azelastine—Alanine aminotransferase increased—Doxorubicin—liver cancer	0.000276	0.00365	CcSEcCtD
Azelastine—Upper respiratory tract infection—Epirubicin—liver cancer	0.000271	0.00359	CcSEcCtD
Azelastine—Asthma—Doxorubicin—liver cancer	0.00027	0.00357	CcSEcCtD
Azelastine—Pollakiuria—Epirubicin—liver cancer	0.00027	0.00357	CcSEcCtD
Azelastine—Nausea—Sorafenib—liver cancer	0.000267	0.00353	CcSEcCtD
Azelastine—Weight increased—Epirubicin—liver cancer	0.000266	0.00351	CcSEcCtD
Azelastine—Bronchitis—Doxorubicin—liver cancer	0.00026	0.00344	CcSEcCtD
Azelastine—Conjunctivitis—Epirubicin—liver cancer	0.000253	0.00335	CcSEcCtD
Azelastine—Upper respiratory tract infection—Doxorubicin—liver cancer	0.000251	0.00332	CcSEcCtD
Azelastine—Pollakiuria—Doxorubicin—liver cancer	0.00025	0.0033	CcSEcCtD
Azelastine—Haematuria—Epirubicin—liver cancer	0.000248	0.00328	CcSEcCtD
Azelastine—Weight increased—Doxorubicin—liver cancer	0.000246	0.00325	CcSEcCtD
Azelastine—Epistaxis—Epirubicin—liver cancer	0.000246	0.00325	CcSEcCtD
Azelastine—Sinusitis—Epirubicin—liver cancer	0.000244	0.00323	CcSEcCtD
Azelastine—Rhinitis—Epirubicin—liver cancer	0.000234	0.0031	CcSEcCtD
Azelastine—Conjunctivitis—Doxorubicin—liver cancer	0.000234	0.0031	CcSEcCtD
Azelastine—Hypoaesthesia—Epirubicin—liver cancer	0.000233	0.00308	CcSEcCtD
Azelastine—Pharyngitis—Epirubicin—liver cancer	0.000232	0.00307	CcSEcCtD
Azelastine—Haematuria—Doxorubicin—liver cancer	0.00023	0.00304	CcSEcCtD
Azelastine—Epistaxis—Doxorubicin—liver cancer	0.000227	0.00301	CcSEcCtD
Azelastine—Sinusitis—Doxorubicin—liver cancer	0.000226	0.00299	CcSEcCtD
Azelastine—Visual impairment—Epirubicin—liver cancer	0.000225	0.00298	CcSEcCtD
Azelastine—Eye disorder—Epirubicin—liver cancer	0.000218	0.00289	CcSEcCtD
Azelastine—Flushing—Epirubicin—liver cancer	0.000217	0.00287	CcSEcCtD
Azelastine—Rhinitis—Doxorubicin—liver cancer	0.000217	0.00287	CcSEcCtD
Azelastine—Hypoaesthesia—Doxorubicin—liver cancer	0.000215	0.00285	CcSEcCtD
Azelastine—Pharyngitis—Doxorubicin—liver cancer	0.000215	0.00284	CcSEcCtD
Azelastine—Visual impairment—Doxorubicin—liver cancer	0.000208	0.00276	CcSEcCtD
Azelastine—Eye disorder—Doxorubicin—liver cancer	0.000202	0.00267	CcSEcCtD
Azelastine—Flushing—Doxorubicin—liver cancer	0.000201	0.00265	CcSEcCtD
Azelastine—Tension—Epirubicin—liver cancer	0.0002	0.00264	CcSEcCtD
Azelastine—Dysgeusia—Epirubicin—liver cancer	0.000199	0.00264	CcSEcCtD
Azelastine—Nervousness—Epirubicin—liver cancer	0.000198	0.00261	CcSEcCtD
Azelastine—Back pain—Epirubicin—liver cancer	0.000197	0.0026	CcSEcCtD
Azelastine—Vision blurred—Epirubicin—liver cancer	0.000192	0.00254	CcSEcCtD
Azelastine—Ill-defined disorder—Epirubicin—liver cancer	0.000189	0.0025	CcSEcCtD
Azelastine—Agitation—Epirubicin—liver cancer	0.000187	0.00247	CcSEcCtD
Azelastine—Tension—Doxorubicin—liver cancer	0.000185	0.00244	CcSEcCtD
Azelastine—Dysgeusia—Doxorubicin—liver cancer	0.000184	0.00244	CcSEcCtD
Azelastine—Malaise—Epirubicin—liver cancer	0.000183	0.00243	CcSEcCtD
Azelastine—Nervousness—Doxorubicin—liver cancer	0.000183	0.00242	CcSEcCtD
Azelastine—Vertigo—Epirubicin—liver cancer	0.000183	0.00242	CcSEcCtD
Azelastine—Back pain—Doxorubicin—liver cancer	0.000182	0.00241	CcSEcCtD
Azelastine—Palpitations—Epirubicin—liver cancer	0.00018	0.00238	CcSEcCtD
Azelastine—Cough—Epirubicin—liver cancer	0.000178	0.00235	CcSEcCtD
Azelastine—Vision blurred—Doxorubicin—liver cancer	0.000177	0.00235	CcSEcCtD
Azelastine—Hypertension—Epirubicin—liver cancer	0.000176	0.00232	CcSEcCtD
Azelastine—Ill-defined disorder—Doxorubicin—liver cancer	0.000175	0.00231	CcSEcCtD
Azelastine—Myalgia—Epirubicin—liver cancer	0.000173	0.00229	CcSEcCtD
Azelastine—Chest pain—Epirubicin—liver cancer	0.000173	0.00229	CcSEcCtD
Azelastine—Agitation—Doxorubicin—liver cancer	0.000173	0.00229	CcSEcCtD
Azelastine—Anxiety—Epirubicin—liver cancer	0.000173	0.00228	CcSEcCtD
Azelastine—Discomfort—Epirubicin—liver cancer	0.000171	0.00226	CcSEcCtD
Azelastine—Malaise—Doxorubicin—liver cancer	0.00017	0.00225	CcSEcCtD
Azelastine—Dry mouth—Epirubicin—liver cancer	0.000169	0.00224	CcSEcCtD
Azelastine—Vertigo—Doxorubicin—liver cancer	0.000169	0.00224	CcSEcCtD
Azelastine—Confusional state—Epirubicin—liver cancer	0.000167	0.00221	CcSEcCtD
Azelastine—Palpitations—Doxorubicin—liver cancer	0.000166	0.0022	CcSEcCtD
Azelastine—Anaphylactic shock—Epirubicin—liver cancer	0.000166	0.0022	CcSEcCtD
Azelastine—Infection—Epirubicin—liver cancer	0.000165	0.00218	CcSEcCtD
Azelastine—Cough—Doxorubicin—liver cancer	0.000164	0.00217	CcSEcCtD
Azelastine—Hypertension—Doxorubicin—liver cancer	0.000163	0.00215	CcSEcCtD
Azelastine—Tachycardia—Epirubicin—liver cancer	0.000162	0.00214	CcSEcCtD
Azelastine—Myalgia—Doxorubicin—liver cancer	0.00016	0.00212	CcSEcCtD
Azelastine—Chest pain—Doxorubicin—liver cancer	0.00016	0.00212	CcSEcCtD
Azelastine—Anxiety—Doxorubicin—liver cancer	0.00016	0.00211	CcSEcCtD
Azelastine—Discomfort—Doxorubicin—liver cancer	0.000158	0.00209	CcSEcCtD
Azelastine—Dry mouth—Doxorubicin—liver cancer	0.000157	0.00207	CcSEcCtD
Azelastine—Confusional state—Doxorubicin—liver cancer	0.000155	0.00205	CcSEcCtD
Azelastine—Anaphylactic shock—Doxorubicin—liver cancer	0.000154	0.00203	CcSEcCtD
Azelastine—Infection—Doxorubicin—liver cancer	0.000153	0.00202	CcSEcCtD
Azelastine—Musculoskeletal discomfort—Epirubicin—liver cancer	0.000151	0.002	CcSEcCtD
Azelastine—Tachycardia—Doxorubicin—liver cancer	0.00015	0.00198	CcSEcCtD
Azelastine—Paraesthesia—Epirubicin—liver cancer	0.000149	0.00197	CcSEcCtD
Azelastine—Dyspnoea—Epirubicin—liver cancer	0.000148	0.00196	CcSEcCtD
Azelastine—Somnolence—Epirubicin—liver cancer	0.000148	0.00195	CcSEcCtD
Azelastine—Fatigue—Epirubicin—liver cancer	0.000143	0.00189	CcSEcCtD
Azelastine—Constipation—Epirubicin—liver cancer	0.000142	0.00188	CcSEcCtD
Azelastine—Pain—Epirubicin—liver cancer	0.000142	0.00188	CcSEcCtD
Azelastine—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.00014	0.00185	CcSEcCtD
Azelastine—Paraesthesia—Doxorubicin—liver cancer	0.000138	0.00182	CcSEcCtD
Azelastine—Dyspnoea—Doxorubicin—liver cancer	0.000137	0.00181	CcSEcCtD
Azelastine—Feeling abnormal—Epirubicin—liver cancer	0.000137	0.00181	CcSEcCtD
Azelastine—Somnolence—Doxorubicin—liver cancer	0.000137	0.00181	CcSEcCtD
Azelastine—Gastrointestinal pain—Epirubicin—liver cancer	0.000136	0.0018	CcSEcCtD
Azelastine—Fatigue—Doxorubicin—liver cancer	0.000132	0.00175	CcSEcCtD
Azelastine—Pain—Doxorubicin—liver cancer	0.000131	0.00174	CcSEcCtD
Azelastine—Constipation—Doxorubicin—liver cancer	0.000131	0.00174	CcSEcCtD
Azelastine—Abdominal pain—Epirubicin—liver cancer	0.000131	0.00174	CcSEcCtD
Azelastine—Body temperature increased—Epirubicin—liver cancer	0.000131	0.00174	CcSEcCtD
Azelastine—Feeling abnormal—Doxorubicin—liver cancer	0.000127	0.00167	CcSEcCtD
Azelastine—Gastrointestinal pain—Doxorubicin—liver cancer	0.000126	0.00166	CcSEcCtD
Azelastine—Hypersensitivity—Epirubicin—liver cancer	0.000122	0.00162	CcSEcCtD
Azelastine—Body temperature increased—Doxorubicin—liver cancer	0.000121	0.00161	CcSEcCtD
Azelastine—Abdominal pain—Doxorubicin—liver cancer	0.000121	0.00161	CcSEcCtD
Azelastine—Asthenia—Epirubicin—liver cancer	0.000119	0.00158	CcSEcCtD
Azelastine—Pruritus—Epirubicin—liver cancer	0.000117	0.00155	CcSEcCtD
Azelastine—Diarrhoea—Epirubicin—liver cancer	0.000114	0.0015	CcSEcCtD
Azelastine—Hypersensitivity—Doxorubicin—liver cancer	0.000113	0.0015	CcSEcCtD
Azelastine—Asthenia—Doxorubicin—liver cancer	0.00011	0.00146	CcSEcCtD
Azelastine—Dizziness—Epirubicin—liver cancer	0.00011	0.00145	CcSEcCtD
Azelastine—Pruritus—Doxorubicin—liver cancer	0.000109	0.00144	CcSEcCtD
Azelastine—Vomiting—Epirubicin—liver cancer	0.000106	0.0014	CcSEcCtD
Azelastine—Diarrhoea—Doxorubicin—liver cancer	0.000105	0.00139	CcSEcCtD
Azelastine—Rash—Epirubicin—liver cancer	0.000105	0.00138	CcSEcCtD
Azelastine—Dermatitis—Epirubicin—liver cancer	0.000105	0.00138	CcSEcCtD
Azelastine—Headache—Epirubicin—liver cancer	0.000104	0.00138	CcSEcCtD
Azelastine—Dizziness—Doxorubicin—liver cancer	0.000102	0.00134	CcSEcCtD
Azelastine—Nausea—Epirubicin—liver cancer	9.86e-05	0.0013	CcSEcCtD
Azelastine—Vomiting—Doxorubicin—liver cancer	9.77e-05	0.00129	CcSEcCtD
Azelastine—Rash—Doxorubicin—liver cancer	9.69e-05	0.00128	CcSEcCtD
Azelastine—Dermatitis—Doxorubicin—liver cancer	9.68e-05	0.00128	CcSEcCtD
Azelastine—Headache—Doxorubicin—liver cancer	9.63e-05	0.00127	CcSEcCtD
Azelastine—Nausea—Doxorubicin—liver cancer	9.13e-05	0.00121	CcSEcCtD
Azelastine—CYP2C19—Metabolism—GGT1—liver cancer	7.42e-06	7.54e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—GOT1—liver cancer	7.42e-06	7.54e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—CYCS—liver cancer	7.38e-06	7.5e-05	CbGpPWpGaD
Azelastine—HRH3—Signaling Pathways—IL6—liver cancer	7.37e-06	7.5e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—CYP2E1—liver cancer	7.37e-06	7.49e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—HMOX1—liver cancer	7.36e-06	7.49e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—GOT1—liver cancer	7.24e-06	7.36e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—GGT1—liver cancer	7.24e-06	7.36e-05	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—PPARG—liver cancer	7.2e-06	7.32e-05	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—MTHFR—liver cancer	7.16e-06	7.28e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—ALDOB—liver cancer	7.15e-06	7.27e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	7.13e-06	7.25e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—KDR—liver cancer	7.06e-06	7.18e-05	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—PPARA—liver cancer	7.03e-06	7.15e-05	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—MTHFR—liver cancer	7.02e-06	7.13e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—MAPK14—liver cancer	7.01e-06	7.13e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—IL2—liver cancer	7.01e-06	7.13e-05	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—MTHFR—liver cancer	7e-06	7.12e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	6.99e-06	7.11e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—TERT—liver cancer	6.99e-06	7.11e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—CYCS—liver cancer	6.95e-06	7.07e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—liver cancer	6.9e-06	7.02e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—CYCS—liver cancer	6.89e-06	7.01e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—PSMD10—liver cancer	6.88e-06	7e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—PSMA4—liver cancer	6.88e-06	7e-05	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—PPARA—liver cancer	6.88e-06	7e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—ESR1—liver cancer	6.88e-06	7e-05	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—PPARA—liver cancer	6.87e-06	6.98e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—GSTM1—liver cancer	6.86e-06	6.98e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—GOT1—liver cancer	6.82e-06	6.94e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—GGT1—liver cancer	6.82e-06	6.94e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—CRABP1—liver cancer	6.82e-06	6.94e-05	CbGpPWpGaD
Azelastine—HRH3—Signaling Pathways—AKT1—liver cancer	6.8e-06	6.91e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—F2—liver cancer	6.8e-06	6.91e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—GOT1—liver cancer	6.77e-06	6.88e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—GGT1—liver cancer	6.77e-06	6.88e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—GOT2—liver cancer	6.7e-06	6.81e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—GSTP1—liver cancer	6.66e-06	6.78e-05	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—MTHFR—liver cancer	6.61e-06	6.73e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—HMOX1—liver cancer	6.57e-06	6.68e-05	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—PIK3CD—liver cancer	6.56e-06	6.67e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—GSTP1—liver cancer	6.5e-06	6.61e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—CYP1A1—liver cancer	6.5e-06	6.61e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—PIK3CG—liver cancer	6.5e-06	6.61e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—APC—liver cancer	6.5e-06	6.61e-05	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—PPARA—liver cancer	6.49e-06	6.6e-05	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—ALB—liver cancer	6.47e-06	6.58e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—HMOX1—liver cancer	6.42e-06	6.52e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—KDR—liver cancer	6.39e-06	6.5e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—MAPK14—liver cancer	6.35e-06	6.46e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—CYP2E1—liver cancer	6.3e-06	6.4e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—ESR1—liver cancer	6.23e-06	6.33e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—F2—liver cancer	6.15e-06	6.26e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—GSTP1—liver cancer	6.13e-06	6.23e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—GSTM1—liver cancer	6.12e-06	6.23e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—BRAF—liver cancer	6.11e-06	6.22e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	6.1e-06	6.2e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—GSTP1—liver cancer	6.08e-06	6.18e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—MTHFR—liver cancer	6.06e-06	6.17e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—HMOX1—liver cancer	6.05e-06	6.15e-05	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—PIK3CG—liver cancer	6.02e-06	6.12e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—HMOX1—liver cancer	5.99e-06	6.09e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—GSTM1—liver cancer	5.98e-06	6.08e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—HPGDS—liver cancer	5.96e-06	6.06e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—PPARA—liver cancer	5.95e-06	6.05e-05	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—PIK3CG—liver cancer	5.89e-06	5.99e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—CYCS—liver cancer	5.89e-06	5.99e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—APC—liver cancer	5.89e-06	5.99e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—PIK3CG—liver cancer	5.89e-06	5.99e-05	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—PIK3CG—liver cancer	5.88e-06	5.98e-05	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	5.83e-06	5.93e-05	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—PPARG—liver cancer	5.81e-06	5.91e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—CYP1A1—liver cancer	5.81e-06	5.9e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—GGT1—liver cancer	5.78e-06	5.88e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—GOT1—liver cancer	5.78e-06	5.88e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—PIK3CD—liver cancer	5.72e-06	5.81e-05	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—PIK3CB—liver cancer	5.72e-06	5.81e-05	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—PPARG—liver cancer	5.69e-06	5.78e-05	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—PPARG—liver cancer	5.68e-06	5.77e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—CYP1A1—liver cancer	5.67e-06	5.76e-05	CbGpPWpGaD
Azelastine—ADRA1B—GPCR downstream signaling—PIK3CA—liver cancer	5.66e-06	5.76e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—SERPINE1—liver cancer	5.65e-06	5.75e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—GSTM1—liver cancer	5.63e-06	5.73e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—KRAS—liver cancer	5.6e-06	5.69e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—GSTM1—liver cancer	5.58e-06	5.68e-05	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—PIK3CG—liver cancer	5.56e-06	5.65e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—BRAF—liver cancer	5.53e-06	5.63e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—MTHFR—liver cancer	5.41e-06	5.5e-05	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—PPARG—liver cancer	5.36e-06	5.45e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	5.34e-06	5.43e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—CYP1A1—liver cancer	5.34e-06	5.43e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—PSMD10—liver cancer	5.31e-06	5.4e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—PSMA4—liver cancer	5.31e-06	5.4e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—PPARA—liver cancer	5.31e-06	5.4e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—CYP1A1—liver cancer	5.29e-06	5.38e-05	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—PIK3CD—liver cancer	5.29e-06	5.38e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—MTHFR—liver cancer	5.28e-06	5.37e-05	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—ALB—liver cancer	5.22e-06	5.31e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—GSTP1—liver cancer	5.19e-06	5.28e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—PPARA—liver cancer	5.18e-06	5.27e-05	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—PIK3CD—liver cancer	5.18e-06	5.27e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—PIK3CD—liver cancer	5.18e-06	5.26e-05	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—PIK3CD—liver cancer	5.17e-06	5.26e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—GOT2—liver cancer	5.17e-06	5.26e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—PIK3CA—liver cancer	5.14e-06	5.23e-05	CbGpPWpGaD
Azelastine—HRH1—GPCR downstream signaling—PIK3CA—liver cancer	5.13e-06	5.21e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—HMOX1—liver cancer	5.12e-06	5.21e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—SERPINE1—liver cancer	5.12e-06	5.2e-05	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—ALB—liver cancer	5.12e-06	5.2e-05	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—ALB—liver cancer	5.1e-06	5.19e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—RAF1—liver cancer	5.1e-06	5.19e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—PIK3CG—liver cancer	5.09e-06	5.18e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—KRAS—liver cancer	5.07e-06	5.15e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—MTOR—liver cancer	4.98e-06	5.07e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—PIK3CB—liver cancer	4.98e-06	5.07e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—MTHFR—liver cancer	4.98e-06	5.06e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—MTHFR—liver cancer	4.94e-06	5.02e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—PPARG—liver cancer	4.92e-06	5e-05	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—PIK3CD—liver cancer	4.89e-06	4.97e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—PPARA—liver cancer	4.88e-06	4.97e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—CYP2E1—liver cancer	4.86e-06	4.94e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—PPARA—liver cancer	4.84e-06	4.92e-05	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—ALB—liver cancer	4.82e-06	4.9e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—GSTM1—liver cancer	4.77e-06	4.85e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	4.77e-06	4.85e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—HRAS—liver cancer	4.76e-06	4.84e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—CDKN1B—liver cancer	4.68e-06	4.76e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—PIK3CA—liver cancer	4.65e-06	4.73e-05	CbGpPWpGaD
Azelastine—ADRA1B—GPCR downstream signaling—AKT1—liver cancer	4.63e-06	4.7e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—RAF1—liver cancer	4.62e-06	4.7e-05	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—PIK3CB—liver cancer	4.61e-06	4.69e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—CASP3—liver cancer	4.58e-06	4.66e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—IL2—liver cancer	4.58e-06	4.65e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—IL6—liver cancer	4.55e-06	4.63e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—PIK3CG—liver cancer	4.55e-06	4.62e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—CYCS—liver cancer	4.55e-06	4.62e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—CYP1A1—liver cancer	4.52e-06	4.6e-05	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—PIK3CB—liver cancer	4.52e-06	4.59e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—MTOR—liver cancer	4.51e-06	4.59e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—PIK3CB—liver cancer	4.51e-06	4.59e-05	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—PIK3CB—liver cancer	4.51e-06	4.58e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—PIK3CD—liver cancer	4.48e-06	4.55e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—GOT1—liver cancer	4.46e-06	4.54e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—GGT1—liver cancer	4.46e-06	4.54e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—CCND1—liver cancer	4.46e-06	4.54e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—JUN—liver cancer	4.45e-06	4.53e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—PIK3CG—liver cancer	4.44e-06	4.51e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—ALB—liver cancer	4.42e-06	4.5e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—CTNNB1—liver cancer	4.42e-06	4.49e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—PPARG—liver cancer	4.39e-06	4.46e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	4.35e-06	4.42e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—MMP9—liver cancer	4.33e-06	4.4e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—CDKN1A—liver cancer	4.32e-06	4.39e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—HRAS—liver cancer	4.31e-06	4.38e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—PPARG—liver cancer	4.28e-06	4.36e-05	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—PIK3CB—liver cancer	4.26e-06	4.33e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—CDKN1B—liver cancer	4.23e-06	4.3e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—MTHFR—liver cancer	4.22e-06	4.29e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—MAPK8—liver cancer	4.21e-06	4.28e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—AKT1—liver cancer	4.2e-06	4.27e-05	CbGpPWpGaD
Azelastine—HRH1—GPCR downstream signaling—AKT1—liver cancer	4.19e-06	4.26e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—PIK3CG—liver cancer	4.18e-06	4.25e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—CASP3—liver cancer	4.15e-06	4.22e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—PIK3CG—liver cancer	4.15e-06	4.22e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—IL2—liver cancer	4.14e-06	4.21e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—PPARA—liver cancer	4.14e-06	4.21e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—IL6—liver cancer	4.12e-06	4.19e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—CCND1—liver cancer	4.04e-06	4.11e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—PPARG—liver cancer	4.04e-06	4.11e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—JUN—liver cancer	4.03e-06	4.1e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—GSTP1—liver cancer	4.01e-06	4.08e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—PPARG—liver cancer	4e-06	4.07e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—CTNNB1—liver cancer	4e-06	4.07e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—PIK3CD—liver cancer	4e-06	4.07e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—HMOX1—liver cancer	3.95e-06	4.02e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—ALB—liver cancer	3.95e-06	4.01e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—MMP9—liver cancer	3.92e-06	3.99e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—CDKN1A—liver cancer	3.91e-06	3.97e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—PIK3CB—liver cancer	3.9e-06	3.97e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—PIK3CD—liver cancer	3.9e-06	3.97e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—VEGFA—liver cancer	3.89e-06	3.96e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—ALB—liver cancer	3.85e-06	3.92e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—STAT3—liver cancer	3.85e-06	3.92e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—MAPK8—liver cancer	3.81e-06	3.88e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—AKT1—liver cancer	3.8e-06	3.87e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	3.72e-06	3.78e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—GSTM1—liver cancer	3.68e-06	3.75e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—PIK3CD—liver cancer	3.68e-06	3.74e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—PIK3CD—liver cancer	3.65e-06	3.71e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—ALB—liver cancer	3.63e-06	3.69e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—ALB—liver cancer	3.6e-06	3.66e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—MYC—liver cancer	3.58e-06	3.64e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—TGFB1—liver cancer	3.57e-06	3.63e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—PIK3CG—liver cancer	3.54e-06	3.6e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—VEGFA—liver cancer	3.52e-06	3.58e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—CYP1A1—liver cancer	3.49e-06	3.55e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—STAT3—liver cancer	3.49e-06	3.54e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—PIK3CB—liver cancer	3.48e-06	3.54e-05	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—PIK3CA—liver cancer	3.48e-06	3.54e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—PPARG—liver cancer	3.42e-06	3.48e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—PIK3CB—liver cancer	3.4e-06	3.46e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—KRAS—liver cancer	3.31e-06	3.36e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—MTHFR—liver cancer	3.25e-06	3.31e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—MYC—liver cancer	3.24e-06	3.29e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—TGFB1—liver cancer	3.23e-06	3.29e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—PIK3CB—liver cancer	3.2e-06	3.26e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—PPARA—liver cancer	3.19e-06	3.25e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—PIK3CB—liver cancer	3.18e-06	3.23e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—PIK3CD—liver cancer	3.11e-06	3.17e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—ALB—liver cancer	3.08e-06	3.13e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—PIK3CA—liver cancer	3.04e-06	3.09e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—KRAS—liver cancer	2.99e-06	3.04e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—TP53—liver cancer	2.94e-06	2.99e-05	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—AKT1—liver cancer	2.85e-06	2.89e-05	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—PIK3CA—liver cancer	2.81e-06	2.86e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—HRAS—liver cancer	2.81e-06	2.86e-05	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—PIK3CA—liver cancer	2.75e-06	2.8e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—PIK3CA—liver cancer	2.75e-06	2.8e-05	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—PIK3CA—liver cancer	2.75e-06	2.79e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—PIK3CG—liver cancer	2.73e-06	2.78e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—PIK3CB—liver cancer	2.72e-06	2.76e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—IL6—liver cancer	2.69e-06	2.74e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—TP53—liver cancer	2.66e-06	2.71e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—PPARG—liver cancer	2.64e-06	2.68e-05	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—PIK3CA—liver cancer	2.6e-06	2.64e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—HRAS—liver cancer	2.54e-06	2.59e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—AKT1—liver cancer	2.48e-06	2.52e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—IL6—liver cancer	2.43e-06	2.48e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—PIK3CD—liver cancer	2.4e-06	2.44e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—PIK3CA—liver cancer	2.38e-06	2.42e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—ALB—liver cancer	2.37e-06	2.41e-05	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—AKT1—liver cancer	2.3e-06	2.34e-05	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—AKT1—liver cancer	2.25e-06	2.29e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—AKT1—liver cancer	2.25e-06	2.28e-05	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—AKT1—liver cancer	2.24e-06	2.28e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—PIK3CA—liver cancer	2.12e-06	2.16e-05	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—AKT1—liver cancer	2.12e-06	2.16e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—PIK3CB—liver cancer	2.1e-06	2.13e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—PIK3CA—liver cancer	2.07e-06	2.11e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—PIK3CA—liver cancer	1.95e-06	1.99e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—AKT1—liver cancer	1.94e-06	1.98e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—PIK3CA—liver cancer	1.94e-06	1.97e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—AKT1—liver cancer	1.74e-06	1.76e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—AKT1—liver cancer	1.69e-06	1.72e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—PIK3CA—liver cancer	1.66e-06	1.68e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—AKT1—liver cancer	1.6e-06	1.62e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—AKT1—liver cancer	1.58e-06	1.61e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—AKT1—liver cancer	1.35e-06	1.37e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—PIK3CA—liver cancer	1.28e-06	1.3e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—AKT1—liver cancer	1.04e-06	1.06e-05	CbGpPWpGaD
